See more : Autoliv, Inc. (0MI0.L) Income Statement Analysis – Financial Results
Complete financial analysis of Sutro Biopharma, Inc. (STRO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sutro Biopharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Aegis Logistics Limited (AEGISCHEM.NS) Income Statement Analysis – Financial Results
- Shanghai DZH Limited (601519.SS) Income Statement Analysis – Financial Results
- Besterra Co., Ltd. (1433.T) Income Statement Analysis – Financial Results
- Equippp Social Impact Technologies Limited (PROINDIA.NS) Income Statement Analysis – Financial Results
- Quantum Graphite Limited (QGL.AX) Income Statement Analysis – Financial Results
Sutro Biopharma, Inc. (STRO)
About Sutro Biopharma, Inc.
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 153.73M | 67.77M | 61.88M | 42.72M | 42.74M | 38.42M | 51.74M | 59.73M |
| Cost of Revenue | 6.82M | 8.29M | 9.77M | 76.96M | 65.61M | 54.26M | 51.90M | 43.55M |
| Gross Profit | 146.92M | 59.48M | 52.11M | -34.24M | -22.88M | -15.84M | -156.00K | 16.18M |
| Gross Profit Ratio | 95.57% | 87.77% | 84.21% | -80.14% | -53.53% | -41.24% | -0.30% | 27.09% |
| Research & Development | 180.43M | 137.17M | 104.40M | 76.96M | 65.61M | 54.26M | 54.64M | 43.55M |
| General & Administrative | 62.58M | 59.54M | 56.00M | 36.82M | 32.59M | 21.38M | 16.37M | 14.82M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 62.58M | 59.54M | 56.00M | 36.82M | 32.59M | 21.38M | 16.37M | 14.82M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -4.35M | 1.91M | -77.00K | 87.00K |
| Operating Expenses | 243.01M | 196.72M | 160.40M | 113.78M | 98.20M | 75.64M | 71.01M | 58.37M |
| Cost & Expenses | 243.01M | 196.72M | 160.40M | 113.78M | 98.20M | 75.64M | 71.01M | 58.37M |
| Interest Income | 14.51M | 3.46M | 577.00K | 1.51M | 4.07M | 1.62M | 273.00K | 251.00K |
| Interest Expense | 23.75M | 3.35M | 3.14M | 4.08M | 4.35M | 1.62M | 612.00K | 0.00 |
| Depreciation & Amortization | 6.82M | 8.29M | 9.77M | 4.30M | 4.78M | 4.54M | 4.99M | 5.66M |
| EBITDA | -67.92M | -105.07M | -98.52M | -23.75M | -46.62M | -32.82M | -14.09M | 7.36M |
| EBITDA Ratio | -44.18% | -185.16% | -150.46% | -152.74% | -109.08% | -75.89% | -27.22% | 12.33% |
| Operating Income | -89.28M | -128.94M | -98.52M | -71.06M | -55.47M | -37.22M | -19.27M | 1.36M |
| Operating Income Ratio | -58.07% | -190.26% | -159.22% | -166.32% | -129.79% | -96.89% | -37.25% | 2.28% |
| Total Other Income/Expenses | 677.00K | 12.24M | -7.01M | 38.93M | -276.00K | 1.91M | -416.00K | 338.00K |
| Income Before Tax | -88.60M | -116.70M | -105.54M | -32.13M | -55.74M | -35.32M | -19.69M | 1.70M |
| Income Before Tax Ratio | -57.63% | -172.20% | -170.55% | -75.20% | -130.44% | -91.93% | -38.05% | 2.85% |
| Income Tax Expense | 18.19M | 2.50M | 3.14M | 4.08M | 8.68M | 3.53M | 535.00K | 87.00K |
| Net Income | -106.79M | -119.20M | -108.68M | -36.21M | -55.74M | -35.32M | -19.69M | 1.70M |
| Net Income Ratio | -69.47% | -175.89% | -175.62% | -84.75% | -130.44% | -91.93% | -38.05% | 2.85% |
| EPS | -1.78 | -2.35 | -2.36 | -1.11 | -2.43 | -6.13 | -2.81 | 0.24 |
| EPS Diluted | -1.78 | -2.35 | -2.36 | -1.11 | -2.43 | -6.13 | -2.81 | 0.24 |
| Weighted Avg Shares Out | 60.16M | 50.74M | 46.12M | 32.57M | 22.96M | 5.76M | 7.00M | 7.00M |
| Weighted Avg Shares Out (Dil) | 60.16M | 50.74M | 46.12M | 32.57M | 22.96M | 5.76M | 7.00M | 7.00M |
Sutro Biopharma (STRO) Rises 9% in the Past Week: Here's Why
Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer
Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Lags Revenue Estimates
Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
VGXI Inc. announces a strategic partnership with Sutro Biopharma Inc. to support growing clinical pipeline
Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
Analysts Estimate Sutro Biopharma, Inc. (STRO) to Report a Decline in Earnings: What to Look Out for
Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial
Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors
Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering
Source: https://incomestatements.info
Category: Stock Reports